| Effect of gasdermin E on the intestinal damage induced by chemotherapy in ovarian cancer |
| Received:May 21, 2021 Revised:September 07, 2021 Click here to download the full text |
| Citation of this paper:LI Ting-ting,LIU Shen-ping,DU Ming.Effect of gasdermin E on the intestinal damage induced by chemotherapy in ovarian cancer[J].Chinese Journal of Clinical Medicine,2022,29(1):35-41 |
| Hits: 1697 |
| Download times: 470 |
| Author Name | Affiliation | E-mail | | LI Ting-ting | Department of Obstetrics and Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, China | | | LIU Shen-ping | Department of Obstetrics and Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, China | | | DU Ming | Department of Obstetrics and Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, China | mutudum@sina.com |
|
| Abstract:Objective To investigate the effect of gasdermin E (GSDME) inhibitor on the intestinal damage of mice with ovarian cancer induced by cisplatin. Methods Z-DMLD-FMK targeted to caspase-3 was administrated to suppress the cleavage and expression of GSDME in mice with ovarian cancer. 40 female C57BL/6 mice aged 6-7 weeks were randomly divided into the normal group and ovarian cancer group (n=20), which were further divided into control group, cisplatin group, GSDME inhibitor group, and cisplatin+GSDME inhibitor group, with 5 mice in each subgroup. Mice in the normal group were treated with cisplatin and GSDME inhibitor separately and jointly after grouping, while mice in the ovarian cancer group were given corresponding intervention 15 days after intraperitoneal injection of ID8 cells. The weight, tumor size, and intestinal damage of mice as well as activation level of GSDME were studied. In vivo fluorescent imaging technology was used to assess tumor size, hematoxylin-eosin (H-E) staining was used to observe the inflammation and intestinal damage of mice, and Western blotting was used to detect the activation level of GSDME in the intestinal tissue. Results The cisplatin significantly reduced the tumor volume of the mice, while GSDME inhibitor had no effect on the tumor burden of the mice. In normal and ovarian cancer mice, the cisplatin group showed a steady decrease in weight, obvious intestinal damage, and increased GSDME activation level in the intestinal tissue compared with the control group (P<0.001). GSDME inhibitor alleviated the weight loss, damage of the digestive tract, and decreased activation level of GSDME which is caused by cisplatin (P<0.05). Conclusion GSDME inhibitor can inhibit the activation level of GSDME in intestinal tissue, thereby reducing intestinal damage and weight loss caused by cisplatin without affecting the chemotherapeutic effect of cisplatin. |
| keywords:gasdermin E pyroptosis intestinal damage ovarian cancer |
| HTML View Full Text View/Add Comment Download reader |
|
|
|